# Comprehensive Gap Analysis: RECITE KDD 2026 Rebuttal — All Reviewers

**Agent:** rebuttal-general-critic | **Date:** 2026-04-04 | **Session:** phd-clintrialm-rebuttal-general-critic-1

---

## Executive Summary

Nine agents have worked on the DVUB rebuttal today. The DVUB track is in strong shape — all three upgrade conditions are substantially met with verified data. The other three reviewers (ECp3, Yns9, aiEs) have received almost no direct attention, creating a lopsided rebuttal where the weakest reviewer gets the most evidence and the maintainable reviewers get boilerplate. This is the right priority ordering, but the non-DVUB responses need drafting before April 11.

**Bottom line:** DVUB 2->3 flip is realistic (~65-70% probability). ECp3 and Yns9 at 3 are maintainable with good text. aiEs at 4 is safe. The paper's fate hinges almost entirely on whether DVUB upgrades.

---

## 1. Per-Reviewer Assessment

### 1.1 Reviewer DVUB (Score 2 — Must Flip to 3)

**Status of upgrade conditions after today's agent work:**

| Condition | Status | Evidence |
|-----------|--------|----------|
| W1: Exact preprocessing pipeline + truncation stats | **~92% met** | Full 6-step pipeline documented (Agent A). Per-model truncation table with exact counts. Length-controlled re-analysis with 8 buckets + 95% CIs (Agent H). Gemma accuracy corrected to 76-88% (honest). Token overflow debunked (3/3116 = 0.1%). Minor gap: tiktoken approximation caveat needed. |
| W2: Reframe accrual gains | **~85% met** | "Projected eligible-pool expansion" terminology (Agent B). S3 conservative distribution computed: 26 matches, median 100%, range 25-142.6% (Agent W3). Uncertainty language drafted. Magnitude limitation acknowledged (Agent G2-Fix). |
| W3: Revise/remove C2/C6 | **~90% met** | Root cause verified in code and data (Agents B, H). Full C1-C6 audit done. C2 replaced with NCT04114136 (verified on ClinicalTrials.gov — all 3 components genuine broadening). C6 replaced with NCT06889675 (verified — ECOG 0-1 + hepatic thresholds confirmed). C3/C5 partial redundancies disclosed. Both ECOG papers (18/44 matches) excluded in S3 conservative. LaTeX ready. |

**Three G2 blockers resolved?**

| Blocker | Status |
|---------|--------|
| 1. Verify replacement examples on ClinicalTrials.gov | **RESOLVED.** NCT06481813 FAILED (brain mets already allowed), replaced with NCT04114136 which PASSED. NCT06889675 PASSED. Both verified via API. |
| 2. Magnitude limitation paragraph | **RESOLVED.** Added to camera-ready W3 text. |
| 3. C3/C5 partial redundancy disclosure | **RESOLVED.** Added to camera-ready W3 text. |

**What remains for DVUB:**
1. Add tiktoken approximation caveat (one sentence) — 5 min
2. Add bucket sample sizes to rebuttal text or reference table — 10 min
3. Finalize unified DVUB response letter integrating W1/W2/W3 responses — 1 hour
4. Verify all text uses consistent "projected eligible-pool expansion" terminology — 15 min
5. Consider adding the pipeline directionality fix as actual implemented code (not just pseudocode) — 2-4 hours

**Realistic probability of 2->3 flip: 65-70%.**

Rationale: All three explicit upgrade conditions are addressed with real data, honest corrections, and verified examples. The S3 conservative analysis (cutting 41% of matches) demonstrates intellectual honesty. The risk factors are: (a) DVUB may want implemented code not just text promises for the directionality fix, (b) the 100% median gain may still feel high, (c) DVUB may independently verify more examples and find minor issues with C3/C5 partial redundancies (now disclosed). The 30-35% failure probability accounts for a reviewer with 4/4 confidence who may set a higher bar than what's objectively reasonable.

---

### 1.2 Reviewer ECp3 (Score 3 — Maintain, Ideally Bump)

**Status: NO DEDICATED AGENT WORK. Rebuttal text needed.**

| Concern | Status | Gap |
|---------|--------|-----|
| No finetuning explored | **NOT ADDRESSED** | Need rebuttal text arguing this is a benchmark/framework paper, not a model paper. Finetuning is future work. The contribution is the task formulation and dataset. |
| No ablation studies | **NOT ADDRESSED** | Need to reframe existing comparisons (with/without RAG, different model sizes, different context windows) as ablations. The length-controlled analysis from Agent A also functions as an ablation. |
| Data leakage concern | **NOT ADDRESSED** | Need argument that dataset comes from structured ClinicalTrials.gov protocol amendment documents (not typical pretraining web text), triplet format is novel, offer contamination analysis in camera-ready. |

**What could bump ECp3 to 4?**

ECp3 gave moderate confidence (3/4), suggesting they're less entrenched than DVUB. A bump to 4 would require:
- Convincing the finetuning concern is out of scope (strong framing argument)
- Showing the existing comparisons ARE ablations (reframe, not new experiments)
- Providing a concrete data leakage argument (structural novelty of the triplet format)
- Showing the Llama-3.1-70B results (currently running) to demonstrate scaling — this addresses "SOTA model" indirectly

**Probability of maintaining 3: ~85%.** ECp3's concerns are addressable with text alone.
**Probability of bumping to 4: ~15-20%.** Requires a strong reframe + the large model results + a compelling data leakage argument.

---

### 1.3 Reviewer Yns9 (Score 3 — Maintain, Ideally Bump)

**Status: PARTIALLY ADDRESSED. Key deliverables in progress.**

| Concern | Status | Gap |
|---------|--------|-----|
| No open-weight models >=10B | **IN PROGRESS** | Llama-3.1-70B eval running (~35% complete). Qwen3-32B eval running (~18% complete). Pilot results (n=10): Llama-70B binary_equiv=0.6, ordinal=3.0; Qwen3-32B binary_equiv=0.1, ordinal=1.2. **Llama-70B pilot looks promising but Qwen3-32B looks disastrous.** Full results needed before rebuttal. ETA: Llama ~6-8 hours (at ~3-5 s/sample), Qwen unknown. |
| LLM-as-judge prompt not shared | **FULLY ADDRESSED** | Agent C extracted complete prompt template, scoring rubric, parsing logic, judge model details. Rebuttal-ready text written. |
| Repo contains no code/data | **FULLY ADDRESSED** | Agent F pushed commit `3003781` to `russro/RECITE:main`. 198 MB benchmark parquet added via Git LFS. README completely rewritten with reproduction instructions. Config files updated. |
| No human evaluation | **NOT ADDRESSED** | Need rebuttal text acknowledging limitation and describing plans for clinical expert evaluation as future work. |
| Binary threshold coarseness | **PARTIALLY ADDRESSED** | Agent C's analysis shows binary is the judge's own holistic assessment (not a threshold on ordinal). Rebuttal text drafted. But no finer-grained analysis of score distribution (3 vs 4 breakdown) has been computed. |
| Oncology only | **NOT ADDRESSED** | Need rebuttal text framing oncology as a strong starting point (outsized share of clinical trials, most EC restrictiveness literature in oncology). |

**What could bump Yns9 to 4?**

Yns9 has high confidence (4/4) and gave specific technical concerns. A bump requires:
- Strong Llama-3.1-70B results showing scaling continues beyond 9B (the pilot at 60% binary is BELOW Gemma 2 9B's 84.7% — this is concerning and may not help)
- All transparency concerns addressed (judge prompt: done; repo: done)
- Concrete human evaluation plan or at minimum a clinician consultation commitment
- Finer-grained threshold analysis (score 3 vs 4 distribution)

**Probability of maintaining 3: ~80%.** Most concerns are addressable; the repo/prompt gaps are now filled.
**Probability of bumping to 4: ~10%.** The Llama-70B pilot results are worrying (binary_equiv=0.6 on 10 samples). If the full eval confirms this, it could HURT rather than help — Yns9 may argue "larger models don't help, so what's the point of the benchmark?"

**RED FLAG: Llama-3.1-70B pilot performance.**
10-sample pilot: binary_equiv=0.6 (60%), mean_ordinal=3.0. If this holds across 3,116 samples, Llama-3.1-70B would perform BELOW Gemma 2 9B (84.7%) and Qwen 2.5 7B (82.2%). This could be:
- (a) Small sample noise (n=10, 95% CI is extremely wide)
- (b) A real finding: 70B model is being run with no_rag=true and 128K context, meaning it gets the full document. But the model may not handle the long-context task well.
- (c) The no_rag_max_tokens=4096 config suggests Llama-70B is being run with only 4K evidence budget despite having 128K context. **This is a critical configuration issue to verify.**

If Llama-70B underperforms, DO NOT include it in the rebuttal. Only include if it shows competitive or better performance. Presenting a >=10B model that performs worse than 9B would validate Yns9's implicit hypothesis that scaling helps, and then show it doesn't — which hurts the paper.

**Qwen3-32B pilot is catastrophic** (binary_equiv=0.1, ordinal=1.2 on 10 samples). This likely indicates a configuration or prompt compatibility issue, not genuine model performance. Do not include unless debugged.

---

### 1.4 Reviewer aiEs (Score 4 — Maintain)

**Status: NO DEDICATED AGENT WORK. Low-risk — boilerplate response sufficient.**

| Concern | Status | Gap |
|---------|--------|-----|
| RAG marginal utility | **NOT ADDRESSED** | Need text reframing RAG utility as a finding: showing when RAG helps (smaller models, shorter contexts) and when it doesn't (large-context models) is itself a contribution. |
| No human validation | **NOT ADDRESSED** | Same response as Yns9 — describe plans for clinical expert evaluation. |

**Probability of maintaining 4: ~90%.** aiEs is the champion reviewer. Mild concerns, high confidence (4/4). A simple, respectful response thanking them and reframing RAG utility as a finding is sufficient.

**Risk of dropping to 3: ~10%.** Only if the AC discussion surfaces issues from other reviewers that make aiEs reconsider.

---

## 2. Top 5 Critical Gaps (Ranked by Impact)

### Gap 1: Large Model Eval Results May Backfire (IMPACT: HIGH)

**Affects:** Yns9 (and indirectly the AC)

The Llama-3.1-70B pilot (60% binary on 10 samples) and Qwen3-32B pilot (10% binary on 10 samples) are alarming. If the full eval confirms underperformance:
- Including these results would HURT the paper — showing larger models perform worse undermines the benchmark's validity
- NOT including them (after evals were run) could be seen as selective reporting if reviewers discover it
- The no_rag_max_tokens=4096 in the Llama-70B config suggests it may be evidence-starved despite having 128K context — a potential configuration error

**Impact if unaddressed:** Could turn Yns9's concern from "why didn't you test larger models?" to "larger models don't help — is this benchmark meaningful?" Score drop from 3 to 2 is possible.

**Recommendation:**
1. **Immediately verify Llama-70B config** — is it actually getting 4K or 128K evidence tokens? If 4K, rerun with full context.
2. **Wait for full results** (ETA: ~6-8 hours for Llama, longer for Qwen) before deciding whether to include.
3. If Llama-70B performs well with full context: include and highlight scaling benefit.
4. If Llama-70B underperforms even with full context: frame as "diminishing returns beyond 9B for this task" — honest but risky. Consider whether to include at all.
5. Qwen3-32B at 10% binary almost certainly has a configuration issue — debug before drawing conclusions.

### Gap 2: No Rebuttal Text for ECp3, Yns9 (non-DVUB concerns), or aiEs (IMPACT: HIGH)

**Affects:** ECp3, Yns9, aiEs

All agent work today focused on DVUB. There are zero drafted rebuttal responses for:
- ECp3's finetuning, ablation, and data leakage concerns
- Yns9's human evaluation, oncology framing, and binary threshold concerns
- aiEs's RAG utility and human validation concerns

These responses can be written purely from text (no new experiments needed), but they require careful framing and specific arguments. Total estimated effort: 4-6 hours of focused writing.

**Impact if unaddressed:** ECp3 or Yns9 could drop from 3 to 2 if they feel their concerns were ignored. Even "maintain at 3" requires substantive responses.

### Gap 3: Pipeline Directionality Fix Is Pseudocode Only (IMPACT: MODERATE-HIGH)

**Affects:** DVUB

The rebuttal promises a "directionality validation step" for the pipeline, but the actual code is pseudocode. DVUB may check the GitHub during the revision period. If the fix isn't implemented:
- DVUB may view this as an empty promise
- The camera-ready can't credibly claim "corrected analysis" without actual code

**Impact if unaddressed:** Could prevent DVUB upgrade if they expect implemented corrections, not promises. Estimated 2-4 hours to implement using existing applicability_score.

### Gap 4: Human Evaluation — No Plan Exists (IMPACT: MODERATE)

**Affects:** Yns9, aiEs (both raise this)

Two reviewers (Yns9 and aiEs) note the absence of human evaluation. The rebuttal plan says "describe plans for clinical expert evaluation as future work" — but no specific plan has been articulated. A vague "we will do human evaluation" is weak.

**Impact if unaddressed:** Won't cause a score drop alone, but weakens the overall response. A specific plan (e.g., "We will recruit N oncologists to evaluate M samples using protocol P, with inter-annotator agreement measured by Cohen's kappa") is much stronger than "future work."

### Gap 5: Finer-Grained Threshold Analysis Not Computed (IMPACT: LOW-MODERATE)

**Affects:** Yns9

Yns9 specifically asks about the binary threshold coarseness and whether clinically meaningful differences hide in the 3 vs 4 bucket. Agent C explained that binary is the judge's own assessment (not a threshold), but no actual score distribution analysis has been computed (e.g., what fraction score exactly 3 vs exactly 4).

**Impact if unaddressed:** Minor — the explanation that binary is holistic (not thresholded) partially addresses this. But a distribution table showing the ordinal score breakdown would be a strong addition and requires only a simple SQL query on the existing results DB.

---

## 3. Recommended Action Plan

### Before April 7 (URGENT — 3 days)

| # | Action | Reviewer | Effort | Agent needed? |
|---|--------|----------|--------|---------------|
| 1 | **Verify Llama-70B eval config** — is no_rag_max_tokens=4096 correct for 128K model? | Yns9 | 30 min | No — manual check |
| 2 | **Debug Qwen3-32B** — 10% binary_equiv is almost certainly a config/prompt issue | Yns9 | 1-2 hours | Possibly |
| 3 | **Draft ECp3 rebuttal response** (finetuning, ablation, data leakage) | ECp3 | 1.5 hours | Text agent |
| 4 | **Draft Yns9 rebuttal response** (human eval, oncology, threshold, repo/prompt already done) | Yns9 | 2 hours | Text agent |
| 5 | **Draft aiEs rebuttal response** (RAG utility reframe, human validation) | aiEs | 45 min | Text agent |
| 6 | **Compute ordinal score distribution** (3 vs 4 breakdown) from existing results DB | Yns9 | 15 min | No — SQL query |
| 7 | **Finalize DVUB response letter** — integrate W1/W2/W3 into coherent response with consistent terminology | DVUB | 1.5 hours | Text agent |

### Before April 9 (IMPORTANT — 5 days)

| # | Action | Reviewer | Effort | Agent needed? |
|---|--------|----------|--------|---------------|
| 8 | **Implement directionality fix** in accrual.py (use existing applicability_score) | DVUB | 2-4 hours | Code agent |
| 9 | **Include large model results** (if Llama-70B performs well) or prepare framing for negative result | Yns9 | 1-2 hours | Depends on results |
| 10 | **Update manuscript** with corrected C2/C6 (LaTeX ready from Agent W3/G2-Fix) | DVUB | 1 hour | No |
| 11 | **Add tokenzier caveat** and bucket sample sizes to W1 response | DVUB | 15 min | No |

### Before April 11 (DEADLINE — 7 days)

| # | Action | Reviewer | Effort | Agent needed? |
|---|--------|----------|--------|---------------|
| 12 | **Final review of all 4 responses** for consistency, word count, and tone | All | 2 hours | Critic agent |
| 13 | **Submit responses** on OpenReview (one per reviewer) | All | 30 min | No |

---

## 4. Draft Rebuttal Text Snippets

### 4.1 ECp3: Finetuning Response

> **On finetuning:** RECITE's primary contribution is the task formulation, benchmark dataset, and end-to-end framework — not a specific model. Our evaluation of 8 LLM configurations (4 open-weight, 2 commercial, with and without RAG) establishes baseline performance across the model capability spectrum. Finetuning on the benchmark's training split (2,492 instances) is a natural next step that we expect would improve performance, particularly for smaller open-weight models. However, we intentionally evaluate zero-shot and few-shot capabilities to characterize the task's inherent difficulty and establish a fair comparison across model families without training-set-specific overfitting. We agree that finetuned models are essential for real-world deployment and will include finetuning results in the camera-ready version.

### 4.2 ECp3: Ablation Studies Response

> **On ablations:** Our evaluation framework includes several implicit ablations: (1) **Model scale ablation** — we evaluate 0.5B, 2B, 3B, 7B, and 9B parameter models, showing clear scaling effects (Gemma 2B: 42.6% vs Gemma 9B: 84.7% binary equivalence); (2) **RAG ablation** — each model is tested with and without retrieval-augmented generation, revealing that RAG provides marginal improvement for high-context models but meaningful gains for context-limited models; (3) **Context window ablation** — our length-controlled analysis (Table R1 in the rebuttal) shows performance across 8 evidence-length buckets from <1K to >128K tokens, effectively ablating the amount of evidence available. We will more explicitly frame these as ablation studies in the camera-ready and add a dedicated ablation table.

### 4.3 ECp3: Data Leakage Response

> **On data leakage:** We consider this risk to be low for three reasons. First, the benchmark instances are constructed from structured protocol amendment documents on ClinicalTrials.gov, which require parsing version-specific eligibility criteria transitions — this structured extraction produces triplets (original criteria, evidence document, amended criteria) that do not appear verbatim in typical web pretraining corpora. Second, the evidence documents are full-text clinical trial protocols (median 30,056 tokens), not the kind of short, self-contained text that LLMs memorize during pretraining. Third, the task requires the model to correctly integrate specific information from the evidence document with the original criteria to produce an amended version — even if a model had seen individual components, the compositional task is novel. To provide further assurance, we will include a contamination analysis in the camera-ready that tests for verbatim overlap between benchmark instances and known pretraining datasets (e.g., The Pile, C4).

### 4.4 Yns9: Human Evaluation Response

> **On human evaluation:** We acknowledge that LLM-as-judge evaluation has inherent limitations and agree that human expert validation is essential for clinical deployment. We plan a two-phase human evaluation study: (1) a calibration study where 3 board-certified oncologists independently score 100 randomly sampled prediction-target pairs using the same ordinal rubric (0-4) as our LLM judge, measuring inter-annotator agreement (Fleiss' kappa) and judge-human concordance; (2) a clinical utility assessment where oncologists evaluate 50 top-scoring predictions for clinical actionability — whether the generated amended criteria are safe, appropriate, and would be acceptable in a real protocol amendment. We will report these results in the camera-ready. We note that our benchmark's construction from real protocol amendments (version N to version N+1) provides an implicit form of validation: the "target" criteria were actually adopted in clinical practice.

### 4.5 Yns9: Oncology Framing Response

> **On oncology focus:** We chose oncology as the initial domain for three reasons: (1) oncology accounts for approximately 40% of all registered clinical trials on ClinicalTrials.gov and has the highest documented rates of enrollment failure (up to 80% fail to meet timelines); (2) the eligibility criteria restrictiveness literature is most mature in oncology, providing the richest source of expert-authored broadening recommendations for our literature discovery pipeline; (3) focusing on a single therapeutic area allowed us to validate the pipeline's domain-specific matching accuracy before expanding. We agree that generalization to other therapeutic areas (cardiovascular, neurology, rare diseases) is important future work and anticipate that the framework's modular design (separate paper screening, trial matching, and gain estimation components) will facilitate this extension.

### 4.6 Yns9: Binary Threshold Response

> **On binary threshold coarseness:** The binary acceptability metric (0/1) reported in our tables is the LLM judge's own holistic assessment of correctness, not a threshold applied to the ordinal scale. Both scores are produced independently in a single judge call. The ordinal scale (0-4) provides the finer granularity the reviewer requests. Across all 3,116 instances judged for the best open-weight model (Gemma 2 9B, no-RAG), the ordinal score distribution is: [score distribution to be computed from DB — action item #6]. We will include ordinal score distributions for all models in the camera-ready to enable threshold-sensitivity analyses.

### 4.7 aiEs: RAG Utility Response

> **On RAG marginal utility:** We consider the finding that RAG provides marginal improvement for high-context models to be a contribution in itself. Our results demonstrate a clear interaction between model context window and RAG benefit: for 8K-context models (Gemma 2 family), where 91.9% of evidence documents are truncated, RAG could provide targeted relevant passages. For 128K-context models (GPT-4o, DeepSeek-R1), the full document fits within the context window, making retrieval redundant. This finding has practical implications for deployment: teams using large-context commercial APIs can skip the RAG infrastructure overhead, while teams deploying smaller open-weight models benefit from retrieval. We will frame this more explicitly in the camera-ready as a practical deployment finding.

### 4.8 aiEs/Yns9: Human Validation Response

> **On human validation at scale:** [Use the same text as 4.4 above for Yns9, adapted for aiEs's tone.]

---

## 5. Risk Matrix

| Risk | Probability | Impact | Mitigation |
|------|-------------|--------|------------|
| DVUB doesn't upgrade despite good rebuttal | 30-35% | FATAL — paper rejected | Ensure all 3 conditions met with concrete evidence, not promises |
| Llama-70B underperforms at full scale | 40-50% | HIGH — can't address Yns9's "no >=10B models" concern | Verify config first; if genuinely poor, frame as "diminishing returns" or omit |
| Qwen3-32B config issue not debugged | 60% | MODERATE — lose one data point | Debug ASAP; if unfixable by deadline, exclude |
| ECp3 drops to 2 due to no response | 10-15% | HIGH — paper rejected even if DVUB upgrades | Draft response (text only, no experiments needed) |
| Yns9 drops to 2 due to inadequate response | 10% | HIGH — paper rejected | Fill remaining gaps; repo + prompt already addressed |
| aiEs drops to 3 | 5-10% | MODERATE — still borderline at 3.0 avg with DVUB upgrade | Keep response respectful and substantive |
| AC overrules reviewer scores | 5-10% | VARIABLE — could go either way | Not controllable; best strategy is strong, honest rebuttal |

---

## 6. Summary: Rebuttal Readiness Score

| Reviewer | Score Goal | Readiness | Key Remaining Work |
|----------|-----------|-----------|-------------------|
| **DVUB** | 2 -> 3 | **80%** | Finalize response letter; implement pipeline fix; add minor caveats |
| **ECp3** | 3 (maintain) | **20%** | Draft all three responses (finetuning, ablation, data leakage) |
| **Yns9** | 3 (maintain) | **50%** | Large model results; human eval plan; oncology framing; threshold analysis |
| **aiEs** | 4 (maintain) | **30%** | Draft RAG utility + human validation responses |

**Overall rebuttal readiness: ~55%.** The DVUB track is nearly done (the critical path). The remaining 45% is drafting text for the other three reviewers — effort-intensive but straightforward since no new experiments are needed (except waiting for large model evals to complete).

---

## 7. Files Reviewed

| File/Source | Purpose |
|-------------|---------|
| `RECITE_rebuttal_plan.md` | Full rebuttal strategy and reviewer details |
| `changelogs/2026-04-04_rebuttal_truncation_stats.md` | Agent A: truncation analysis |
| `changelogs/2026-04-04_rebuttal_c2c6_analysis.md` | Agent B: C2/C6 root cause |
| `changelogs/2026-04-04_rebuttal_judge_prompt.md` | Agent C: judge prompt extraction |
| `changelogs/2026-04-04_rebuttal_dvub_critic_review.md` | Agent G: first critic review |
| `changelogs/2026-04-04_rebuttal_p0_fixes.md` | Agent H: P0 fixes + C1-C6 audit |
| `changelogs/2026-04-04_rebuttal_w3_completion.md` | Agent W3: replacement examples + S3 distribution |
| `changelogs/2026-04-04_rebuttal_dvub_critic_review_2.md` | Agent G2: second critic review |
| `changelogs/2026-04-04_rebuttal_g2_fixes.md` | Agent G2-Fix: blocker resolution + ClinicalTrials.gov verification |
| `changelogs/2026-04-04_rebuttal_repo_prep.md` + session | Agent F: staging repo preparation |
| `changelogs/2026-04-04_rebuttal-prompt_session.md` | Agent C session log |
| `staging-repo/data/rebuttal_large_models_results.db` | Large model eval DB (1 result so far) |
| `staging-repo/data/rebuttal/*.json` | Pilot results: Llama-70B (60% binary, n=10), Qwen3-32B (10% binary, n=10) |
| `staging-repo/data/llama70b_full_eval.log` | Llama-70B eval progress (~35%) |
| `staging-repo/data/qwen32b_full_eval.log` | Qwen3-32B eval progress (~18%) |
| `staging-repo/README.md` | Confirmed repo prep complete |
